Rigel Chasing Pfizer in RA, Nabs $1.2B-Plus Deal

February 2010
Bioworld Week;2/22/2010, Vol. 18 Issue 8, p1
The article reports on the demand for Rigel Pharmaceuticals Inc. to address the race for oral and disease-modifying rheumatoid arthritis drugs in the U.S. It notes that the move is backed with some big pharmaceutical industry for more than 1 billion dollar deal with AstraZeneca PLC. It stresses that AstraZeneca has licensed a worldwide rights to fostamatinib disodium (R788), a spleen tyrosine kinase inhibitor that has completed Phase II testing.


Related Articles

  • Rigel Celebrates Stock Rise with $135M Offering.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p2 

    The article reports on the increase int the stock price resulting from the positive rheumatoid arthritis data of Rigel Pharmaceuticals Inc. in San Francisco, California, which took advantage of it by raising $135 million in a public offering. The price increase is a big change for a firm that...

  • Rigel Tumbles on Phase III RA Failure; Lilly Drug Misses, Too. Shaffer, Catherine // BioWorld Today;12/14/2012, Vol. 23 Issue 242, p1 

    This article reports on how AstraZeneca plc's results from a Phase IIb study of fostamatinib in rheumatoid arthritis (RA) send shares of partner Rigel Pharmaceuticals Inc. plunging by almost 35 percent on December 13, 2012. Findings from the study showed that the drug was superior to placebo at...

  • Not So 'Fost'? Rigel RA Drug Could Survive AstraZeneca Hit. Osborne, Randy // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1 

    The article discusses the predicament of fostamatinib, the inhibitor for rheumatoid arthritis, after the biopharmaceutical company AstraZeneca terminated its license with Rigel Pharmaceuticals due to the Phase II study results. The experimental drug achieved a high ACR20 score, but was below the...

  • Feature Analysis.  // PharmaWatch: Biotechnology;Apr2010, Vol. 9 Issue 4, p18 

    The article reports on the partnership between Rigel Pharmaceuticals Inc. and AstraZeneca PLC for the development program of R788 (fostamatinib sodium) in treating rheumatoid arthritis (RA). It mentions that R788 is a small molecule spleen tyrosine kinase (Syk) inhibitor which gave positive...

  • AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty.  // PharmaWatch: Monthly Review;Apr2010, Vol. 9 Issue 4, p19 

    The article discusses the future of Rigel Pharmaceuticals Inc.'s R788 rheumatoid arthritis (RA) development program after its Phase III clinical trial failed to demostrate its efficacy for biologic-failures patients. It states that the company has entered a license agreement with AstraZeneca...

  • Rigel Chasing Pfizer in RA; Nabs $1.2B-Plus AstraZeneca Alliance. Boggs, Jennifer // BioWorld Today;2/17/2010, Vol. 21 Issue 31, p1 

    This article deals with the effort of Rigel Pharmaceuticals Inc. to compete with Pfizer in the development of an oral, disease-modifying rheumatoid arthritis drug. Particular focus is given to Rigel's potential licensing deal with AstraZeneca PLC. There is a plan by the pharmaceutical firm to...

  • Licensing Update.  // PharmaWatch: Biotechnology;Apr2010, Vol. 9 Issue 4, p21 

    The article offers updates on licensing agreements of biotechnology companies. AstraZeneca PLC and Rigel Pharmaceuticals sign an exclusive licensing agreement for fostamatinib disodium in treating rheumatoid arthritis (RA). Basilea Pharmaceutica International Ltd. enters license agreement with...

  • Rigel Takes Hit on R788 Data.  // Bioworld Week;8/3/2009, Vol. 17 Issue 31, p2 

    The article reports on the impact of the result of the midstage study of rheumatoid arthritis drug R788 conducted by Rigel Pharmaceuticals Inc. on partnership talks in the U.S. According to the company, the result which failed to hit the mark, will complicate partnership talks but will not end...

  • AstraZeneca, Rigel Focus On Asthma Treatment.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p55 

    The article reports that AstraZeneca PLC is paying Rigel Pharmaceuticals Inc. $1million for exclusive worldwide rights to Regel's inhaled JAK inhibitor R256.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics